Abstract. Changes in the carbohydrate structure on the surface of tumor cells is an important feature of cancer metastasis. The specific role of sialic acids in the glycoconjugate terminal has not yet been clearly elucidated in these processes. Previously, we reported that α2,3-sialic acid residues in breast cancer are associated with metastatic potential. The α2,3-sialyltransferase ST3Gal III, which adds α2,3-sialic acids to glycoproteins, is overexpressed in various tumors, and enzyme activity is correlated with tumor metastasis, yet its mechanistic role has not been fully evaluated. In the present study, we aimed to investigate the influence of ST3Gal III on key steps in the process of breast cancer metastasis. ST3Gal III-overexpressing and ST3Gal III-silenced breast cancer MDA-MB-231 cell lines were generated. They showed an increase or decrease in the tumor-associated antigen sialyl-Lewis X (SLeX). The E-selectin binding capacity of the transfectants was proportional to cell surface SLeX levels. Cell migration and invasion were positively correlated with ST3Gal III levels. Moreover, ST3Gal III expression modulated the protein expression of invasion-related molecules, including β 1 integrin, matrix metalloproteinase (MMP)-2, MMP-9 and cyclooxygenase-2, which may account for the mechanism involved in the effects of ST3Gal III on breast cancer invasiveness. In conclusion, our findings in these novel models of ST3Gal III expression revealed a critical requirement for ST3Gal III in several steps of breast cancer metastasis. ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules. This study provides novel insights into the mechanisms underlying metastasis and suggests a new target for the effective drug treatment of breast cancer metastasis.
Introduction
Changes in the carbohydrate structure on the surface of tumor cells are an important feature of cancer metastasis. Sialic acid, which is ubiquitous at terminal positions of glycoconjugates and bears net charge, has attracted the increased attention of researchers (1) . However, the role of sialic acids in the processes involved in cancer metastasis has not been clarified. Previously we reported that α2,3-sialic acid residues in breast cancer are associated with metastatic potential. α2,3-sialyltransferase ST3Gal III transfers sialic acid with α2,3-linkage to Gal residues located on either Galb1-4GlcNAc or Galb1-3GlcNAc structures (2) .
Changes in ST3Gal III expression have been reported in several types of tumors. In breast cancer, high expression of ST3Gal III was found to be positively correlated with the number of axillary lymph nodes and reduced patient overall survival (3, 4) . In extrahepatic bile duct carcinoma, ST3Gal III levels are correlated with metastasis and poor prognosis (5) . In squamous cell carcinoma of the cervix, ST3Gal III expression levels were obviously increased in patients with lymph node metastasis when compared to levels in patients without metastases (6, 7) . In colon cancer, ST3Gal III expression was increased in carcinoma specimens compared with that in non-malignant colorectal mucosa (8) . In gastric cancer, high levels of ST3Gal III were found to be correlated with tumor recurrence (9) .
Although ST3Gal III expression correlates with tumor progression in various types of carcinomas (10) , the mechanism of ST3Gal III in the process of metastasis has not been fully clarified. ST3Gal III is involved in the biosynthesis of sialyl-Lewis antigens, which can bind to E-selectin expressed on activiated endothelial cells and mediate hematogenous metastasis (11) (12) (13) . In the present study, we investigated the specific influence of ST3Gal III on key steps in breast cancer progression, such as adhesion, migration and metastasis. Toward this aim, we chose two breast cancer cell lines MDA-MB-231 and Bcap37, with different ST3Gal III expression, and we generated an ST3Gal III-overexpressing cell line and downregulated ST3Gal III expression in a cell line by lentiviral transfection. ST3Gal III expression was proportional to sialyl-Lewis X (SLeX) levels and modulated the abilities of binding to E-selectin, cell migration and cell invasion. furthermore, changes in expression of invasion-related molecules, including β 1 integrin, matrix metalloproteinase (MMP)-2, MMP-9 and cyclooxygenase-2 (COX-2) were found in both cell models, which could explain the effect of ST3Gal III on breast cancer cell adhesion and invasion.
In conclusion, our findings in these novel models of ST3Gal III expression revealed a critical requirement for ST3Gal III in several steps of breast cancer metastasis. ST3Gal III modulated breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules. This study provides new insights into the mechanisms underlying metastasis and presents a new target for the effective drug treatment of breast cancer metastasis.
Materials and methods
Stable transfection. The construct human α2,3-sialyltransferase (human ST3Gal III) and short hairpin RNAs (shRNAs) targeting ST3Gal III and cloned into a lentivirus were synthesized by Suzhou GenePharma (Suzhou, China). The nucleotide sequence was confirmed by DNA sequencing. The encoding ST3Gal III lentivirus vector, four shRNA sequences targeting the ST3Gal III lentivirus vector and the empty lentivirus vector were transfected into human breast cancer cell lines MDA-MB-231 and Bcap37 (purchased from the Chinese Academy of Sciences Cell Bank, Shanghai, China) with different ST3Gal III expression. Stable transfected cells were selected with 2 µg/ml puromycin (InvivoGen, San Diego, CA, USA), and resistant clones were further confirmed by real-time PCR and western blot analysis. The stable  ST3Gal III-transfected MDA-MB-231 cells (ST3), shRNA  targeting ST3Gal III-transfected MDA-MB-231 cells  (shRNA-1 , shRNA-2, shRNA-3 and shRNA-4, respectively), mock-transfected cells (M) and parental cells (P) were used in this study. Cells were cultured in L15 medium (Gibco™ Invitrogen Corp., Carslbad, CA, USA) containing 10% fetal bovine serum (fBS), 100 U/ml penicillin and 100 mg/ml streptomycin. Stable transfectants were supplemented with 2 µg/ml puromycin. Cells were fed every 3 days at 37˚C in a humid atmosphere of 5% CO 2 and harvested by 0.25% trypsin. Cell growth and morphology were daily assessed under a field microscope.
Culture conditions for the transfected cells.
ST3Gal III expression by real-time quantitative PCR. Total cellular RNA was extracted using TRIzol reagent (Invitrogen). Quantitative real-time PCR was performed using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's instructions. for real-time PCR, we used ST3Gal III gene forward, 5'-AGAGA AGGACGGTGCCAAG-3' and reverse, 5'-CTGAATGAGGCT GAGTGCTG-3'; β-actin gene forward, 5'-GTGGACATCC GCA AAGAC-3' and reverse, 5'-GAAAGGGTGTAACGCA ACT-3'. The following standard thermal profile was used for all PCRs: 95˚C for 10 min; 40 cycles of 95˚C for 10 sec and 60˚C for 31 sec. For each sample dilution, logarithmic increase in fluorescence signal (DRn) was obtained. DRn threshold was set at 0.02 to obtain the corresponding Ct (threshold cycle) values. The endogenous housekeeping gene β-actin was used to normalize the results. Results are expressed as mean ± SD.
Flow cytometric analysis. Detection of oligosaccharide epitopes on the cell surface was performed by indirect fluorescence. Cells (5x10 5 ) were incubated with anti-SLeX monoclonal antibodies (MAbs) (Calbiochem, EMD Chemicals Inc., San Diego, CA, USA) at 4˚C for 30 min. After washing, the cells were incubated with the secondary antibody Alexa fluor 594 goat anti-mouse IgG (Invitrogen Life Technologies, Frederick, MD, USA). Antibodies were diluted in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA). Mean fluorescence intensity (MfI) was calculated using FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). For each sample three independent assays were performed.
E-selectin binding assay. Adhesion of breast cancer cells to recombinant human E-selectin (rh-E-selectin) was performed. 96-well plates were coated with rh-E-selectin (R&D Systems, Inc., Minneapolis, MN, USA) for 30 min. The plates were blocked and 1x10 5 viable M, P, ST3 or shRNA-2, shRNA-4 cells, were added and incubated at 37˚C for 1 h. In the selected experiments, the cells were previously incubated with antiSLeX MAbs for 30 min at 4˚C. After washes, the adherent cells were fixed with methanol for 30 min. After drying, the fixed cells were stained with 0.1% crystal violet for 30 min, and then washed and dissolved in 10% acetic acid. The optical densities of each well were measured by an ELISA reader at 570 nm. All the experiments were performed in quintuplicate, and three independent assays were carried out. Results are expressed as the mean ± SD.
Tumor cell adhesion assay to HUVECs. Human umbilical vein endothelial cells (HUVECs) (purchased from the Chinese Academy of Sciences Cell Bank) were incubated for 12 h with 10 ng/ml recombinant interleukin IL-1β (R&D Systems, Inc.). Cells were stained with calcein (Invitrogen Life Technologies) in L15 solution. After washing, the cells were resuspended and added to a 96-well plate and cultured with HUVECs. The plates were incubated at 37˚C for 30 min, and then washed three times and the number of adhesive cells was counted under a fluorescence microscope. Results are expressed as the mean ± SD. Each experiment was performed in triplicate wells and three independents assays were carried out.
Cell migration and invasion assays.
Tumor cell migration and invasion were assessed using Transwell chamber (Corning Costar, Inc., Corning, NY, USA). Briefly, Matrigel was used to coat the upper chamber for the invasion assay (not for the migration assay). Cells (1x10 5 ) were added to the upper chamber in serum-free medium, and the lower compartment was filled with media supplemented with 10% fBS. After incubation at 37˚C for 24 h, the non-migrating cells on the upper surface of the filter were removed with cotton swabs, and the migrating cells on the lower surface were fixed and stained with 0.1% crystal violet for 30 min, then photographed under a fluorescence microscope and incorporated dye was dissolved in 10% acetic acid. The optical densities of each well were measured by ELISA reader at 570 nm. Experiments were performed in triplicate.
Western blot analysis. Total cellular proteins were extracted. Equivalent amounts of cellular protein were electrophoresed on 10% SDS-PAGE gel and transfered to nitrocellullose membranes (Millipore Corp., Billerica, MA, USA) and blocked in 5% non-fat milk in TBST for 1 h at room temperature. The cells were incubated with primary antibodies to human ST3Gal III (Abcam, Cambridge, MA, USA), MMP-9, MMP-2 (Cell Signaling Technology, Inc., Beverly, MA, USA), β 1 integrin (Chemicon, Temecula, CA, USA), COX-2 and GAPDH (both from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) in 5% non-fat milk at 4˚C overnight. The membranes were washed with TBST and incubated with horseradish peroxidase-conjugated secondary antibody in 5% non-fat milk for 1 h at room temperature. Immune complexes were detected by enhanced chemoluminescence techniques (Amersham Life Science, Piscataway, NJ, USA). Band densities were quantified by using BandScan software.
Statistical analysis. The data are expressed as the mean ± SD and were analyzed by SPSS 17.0 statistical software to evaluate the statistical difference. P<0.05 was considered to indicate a statistically significant result. One-way ANOVA analysis was used to evaluate all quantitative data.
Results

Stable expression of ST3Gal III in MDA-MB-231 variant cells.
To explore the role of ST3Gal III in breast cancer metastasis, the human ST3Gal III gene, and shRNA targeting ST3Gal III were cloned to lentiviral vectors. Breast cancer cells, MDA-MB-231 and Bcap37, were transfected with the lentiviral vector encoding the human ST3Gal III gene and MDA-MB-231 cells were transfected with ST3Gal III shRNAs. Parental cells were concomitantly transfected with the empty lentiviral vector. Stable cell clones were selected by puromycin and the mRNA levels of ST3Gal III were quantified by real-time PCR (Fig. 1A) . ST3Gal III mRNA expression in the stable ST3Gal III-transfected MDA-MB-231 cells (ST3 cells) was 1.846-fold higher (P<0.05) than that in the parental (P) cells. for the Bcap37 cell model, there was no significant difference between the Bcap37 ST3 and P cells (data not shown). In contrast, ST3Gal III mRNA expression was 3. ST3Gal III modulates de novo expression of SLeX. The synthesis of SLeX structures was catalyzed by ST3Gal III. The levels of SLeX could resort to ST3Gal III enzyme activities. Carbohydrate structure on the cell surface was studied by flow cytometry using specific MAbs against SLeX. The results revealed that ST3 clones displayed a large increase in SLeX expression and a significant decrease in SLeX expression was observed in the shRNA-2 and shRNA-4 transfected cells, compared to the controls (P<0.05) ( fig. 2 ).
Breast cancer cell binding to rh-E-selectin is correlated
with SLeX levels. SLeX present on the tumor cell surface can mediate tumor hematogenous spread by binding to E-selectin expressed on activated endothelial cells. rh-E-selectin binding assays were used to analyze whether the different levels of SLeX expression could regulate changes in the adhesion to rh-Eselectin. As shown in fig. 3 , both cell clones showed different adhesion patterns. The capacity for adhesion to rh-E-selectin was enhanced in the ST3 cells with higher SLeX expression compared with that in the M and P cells (P<0.05). Obviously, lower adhesion to rh-E-selectin was noted in the shRNA-2 and shRNA-4 transfected cells than that noted in the M and P cells (P<0.05), which was consistent with the lower expression level of SLeX. To further confirm that SLeX expression induced by ST3Gal III caused regulation of rh-E-selectin binding, we preincubated both cell clones with anti-SLeX MAb. Cell adhesion to E-selectin was significantly decreased in the ST3 cells (P<0.05), whereas shRNA cells, which had lower SLeX expression levels, did not show a significant change in adhesion capacity to rh-E-selectin. Moreover, there was no different adhesion ability among the groups after incubation. These results demonstrated that the E-selectin binding capacity of the transfectants was proportional to cell surface SLeX levels.
ST3Gal III expression mediates breast cancer cell adhesion to
HUVECs. We next determined the adhesion of the MDA-MB-231 cells with different ST3Gal III expression levels to HUVECs pretreated with IL-1β. ST3 cells with high SLeX expression had a higher adhesion to HUVECs, and shRNA-2, shRNA-4 cells showed significantly decreased adhesion to HUVECs, compared with that observed in the M and P cells (P<0.05) (fig. 4) . These data showed that ST3Gal III and SLeX play an important role in mediating breast cancer adhesion to HUVECs. 
ST3Gal III induces the expression of COX-2, β 1 integrin, MMP-2 and MMP-9.
To further investigate the molecular mechanism of ST3Gal III in modulating cell migration and invasion, we examined the protein expression of invasion-related molecules, COX-2, β 1 integrin, MMP-2 and MMP-9 using western blot analysis. The results showed that ST3Gal III-overexpressing ST3 cells had increased COX-2 ( fig. 6A), β 1 integrin (fig. 6C ), MMP-2 and MMP-9 expression (P<0.05) (fig. 6E) . Moreover, the expression of COX-2 ( fig. 6B), β 1 integrin (fig. 6D ), MMP-2 and MMP-9 ( fig. 6f) were downregulated in the shRNA-2 and shRNA-4 cells (P<0.05). These results showed that ST3Gal III induced the expression of COX-2, β 1 integrin, MMP-2 and MMP-9.
Discussion
Our previous study showed that α2,3-sialic acid residues in breast cancer are associated with metastatic potential (14) . We used α2,3-sialyltransferase ST3Gal III-overexpressing clone ST3 and shRNA-targeted ST3Gal III clone shRNA cells, and extended our study to investigate the mechanistic role of ST3Gal III in the process of metastasis, such as adhesion, migration and invasion in MDA-MB-231 breast cancer cell lines. The results showed that ST3Gal III expression increased sialylation structure SLeX expression. ST3Gal III regulated the abilities of breast cancer cell binding to rh-E-selectin and IL1-β-pretreated HUVECs, via SLeX-E-selectin interaction. In addition, a positive correlation between invasive capacity and ST3Gal III expression was found. Our finding showed that ST3Gal III expression plays a critical role in several steps of the process of breast cancer metastasis.
The molecular mechanisms regulating breast cancer metastasis are still poorly understood. Sialic acids overexpressed in some tumors have the potential to modulate interactions between molecules and cells. One crucial molecule is SLeX with α2,3-sialic acid residues, which involves the attachment of tumor cells to activated endothelial cells. SLeX has been reported to participate in the processes of extravasation by interacting with E-selectin (15, 16) . Several studies have reported that SLeX expression is directly correlated with the binding to endothelial cells via E-selectin-SLeX interaction in colon cancer (17) , H7721 hepatocarcinoma (18) and lung adenocarcinoma cells (19) . In agreement with these data, our results showed that the ST3Gal III-overexpressing ST3 cells exhibited enhanced adherence to rh-E-selectin and the ST3Gal III-silenced shRNA cells had reduced adhesion ability. Moreover, when studying the adhesion of breast cancer cells to IL-1β-stimulated HUVECs, similar results further demonstrated that ST3Gal III and SLeX levels were correlated with E-selectin expressed on HUVECs. When we pretreated ST3 cells with anti-SLeX, the enhanced adhesion was obviously decreased, whereas shRNA cells with low SLeX levels had no significant change. After incubation, there was no difference among the groups, which could account for breast cancer cells binding to stimulated HUVECs mediated by SLeX.
Cell migration and invasion are multistep processes that play pivotal role in cancer metastasis. To our knowledge, α2,3-sialic acid residues are associated with the migration processes in cancer. When α2,3-sialic acid levels on the tumor cell surface were increased, cell migration was significantly enhanced (20) . We aimed to ascertain whether ST3Gal III expression and the subsequent changes in α2,3-sialic acid levels have a role in invasion in MDA-MB-231 breast cancer cells. ST3Gal III-overexpressing ST3 cells exhibited high migration and invasion abilities, whereas ST3Gal III-silenced shRNA cells demonstrated lower invasion capabilities when compared with the mock and parental cells, which was in agreement that α2,3-sialic acid expression resulted in a more invasive phenotype in vitro (21) . In addition, both cell clones ST3 and shRNA displayed different amounts of SLeX expression, which consequently show a different invasive potential. These results reinforce the importance of α2,3-sialic acids in potentiating cell invasion and metastasis. In accordance, decreased α2,3-sialic acid levels in a cancer model resulted in suppression of invasion and metastasis in lung cancer (22) and hepatocarcinoma (23) . Moreover, migration was inhibited after sialic acid residue was elimination (24) . To the best of our knowledge, this is the first report concerning a positive correlation between cell migration and ST3Gal III expression levels in breast cancer cells.
Integrins as extracellular matrix (ECM) adhesion molecules, are involved in metastatic progression, such as the formation of invadopodia (25) , the interaction of metastatic tumor cells with their surrounding ECM (26) , and acquisition of invasive behavior (27) . The levels of β 1 integrin are correlated with metastatic potential. The results described here suggest that the ST3Gal III gene regulates the levels of β 1 integrin expression. We found that β 1 integrin expression was constitutively increased in the ST3Gal III-overexpressing ST3 cells, while low expression was noted in the ST3Gal III-silenced shRNA cells, which could be the machanism involved in the influence on cell invasion abilities. Several studies have demonstrated that sialylation influences migration capability by modulating the integrin function (28, 29) . Thus, we infer that ST3Gal III could alter the sialylation levels of β 1 integrin, modulating their metastatic potential. Nevertheless, further investigations are required to address this issue.
COX-2 is undetectable in most normal tissues but can be induced in many cancers. High COX-2 expression has been reported in colon (30) , bladder (31) , and breast (32) cancers, and is associated with cell motility and invasion (33) , angiogenesis (34) , and lymph node metastasis (35) . Interestingly, all these cancers show increased expression of ST3Gal III. The relationship between ST3Gal III and COX-2 protein expression was investigated. The results found that the ST3Gal III gene could induce the expression of COX-2. COX-2 expression was increased in the ST3 cells with ST3Gal III overexpression, and downregulated in the ST3Gal III-silenced shRNA cells compared with the mock and parental cells, which could be one of the mechanism of the influence on cell invasion abilities mediated by ST3Gal III.
MMP-9 and MMP-2, are important isoforms in the MMP family, and have been reported to be overexpressed and degrade collagen and gelatin, which can aid cell migration and angiogenesis (36) . Recently, it was shown that expression of MMP-9 has been associated with shorter survival rates in breast cancer patients (37) . Additionally, the pulmonary metastasis ability of cancer cells was found to be reduced in MMP-2-or MMP-9-deficient mice compared to wild-type mice (38) and cancer cell proliferation was suppressed in tumors obtained from MMP-9-knockout mice (39). Our results found that ST3 cells with ST3Gal III overexpression had increased expression of MMP-2 and MMP-9, which was decreased in the ST3Gal III-silenced shRNA cells, which may have resulted in the breast cancer cell invasion abilities mediated by ST3Gal III.
Tumor invasion and metastasis are known to be the major causes of mortality in breast cancer patients. In the present study, we engineered stable transfectants of ST3Gal III-overexpressing clone and shRNA-targeted ST3Gal III clones to globally evaluate the role of ST3Gal III in key steps of the process of breast cancer metastasis. In the present study, we demonstrated that ST3Gal III and its downstream product SLeX, conferred to breast cancer cells high adhesion to E-selectin, high migration and invasion capacities, and regulated expression of invasionrelated molecules β 1 integrin, COX-2, MMP-9 and MMP-2. In addition to the role of ST3Gal III in these key steps, this enzyme has been reported to produce resistance to Taxol therapy in ovarian cancer cells (40) . This study highlights the importance of ST3Gal III in cancer processes. A next step would be to further design inhibitors targeted ST3Gal III that may inhibit breast cancer metastasis.
